Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Oesterling

Showing results (51-60 of 220) with videos related to

Pageof 22
Sort By:
The Urologic Clinics of North America|May 1, 1997
Prostate-specific antigen densityM C Beduschi, J E Oesterling
Urology|December 1, 1996
The clinical usefulness of percent free-PSAA W Partin, J E Oesterling
Hepatology (Baltimore, Md.)|July 1, 1988
Influence of male hormones on rates of ethanol elimination in manE Mezey, J E Oesterling, J J Potter
Geriatrics|March 25, 1998
Benign prostatic hyperplasia: use of drug therapy in primary careR Beduschi, M C Beduschi, J E Oesterling
World Journal of Urology|January 1, 1997
Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomyM C Beduschi, R Beduschi, J E Oesterling
Urology|June 3, 1998
Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonistM C Beduschi, R Beduschi, J E Oesterling
The Urologic Clinics of North America|May 1, 1997
Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigenP A Abrahamsson, H Lilja, J E Oesterling
The Journal of Urology|April 1, 1986
Xeroradiography and ultrasonography in the evaluation of a penile injuryJ E Oesterling, W D Bromberg, P C Albertsen
The Journal of Urology|May 1, 1994
Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasiaJ M Monda, M J Barry, J E Oesterling
The Journal of Urology|May 1, 1994
Re: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinomaS J Jacobsen, J E Oesterling, H A Guess
Pageof 22

Showing results (51-60 of 220) with videos related to

Sort By:
Pageof 22
The Urologic Clinics of North America|May 1, 1997
Prostate-specific antigen densityM C Beduschi, J E Oesterling
Urology|December 1, 1996
The clinical usefulness of percent free-PSAA W Partin, J E Oesterling
Hepatology (Baltimore, Md.)|July 1, 1988
Influence of male hormones on rates of ethanol elimination in manE Mezey, J E Oesterling, J J Potter
Geriatrics|March 25, 1998
Benign prostatic hyperplasia: use of drug therapy in primary careR Beduschi, M C Beduschi, J E Oesterling
World Journal of Urology|January 1, 1997
Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomyM C Beduschi, R Beduschi, J E Oesterling
Urology|June 3, 1998
Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonistM C Beduschi, R Beduschi, J E Oesterling
The Urologic Clinics of North America|May 1, 1997
Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigenP A Abrahamsson, H Lilja, J E Oesterling
The Journal of Urology|April 1, 1986
Xeroradiography and ultrasonography in the evaluation of a penile injuryJ E Oesterling, W D Bromberg, P C Albertsen
The Journal of Urology|May 1, 1994
Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasiaJ M Monda, M J Barry, J E Oesterling
The Journal of Urology|May 1, 1994
Re: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinomaS J Jacobsen, J E Oesterling, H A Guess
Pageof 22